Top-Rated StocksTop-RatedNASDAQ:DMRA Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis $26.84 +0.57 (+2.17%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Damora Therapeutics, Inc. Common Stock Stock (NASDAQ:DMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DMRA alerts:Sign Up Key Stats Today's Range$25.63▼$27.7850-Day Range$26.27▼$32.9952-Week Range$2.53▼$38.33Volume639,768 shsAverage Volume383,075 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingBuy Company Overview Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue. Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment. Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.AI Generated. May Contain Errors. Read More Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreDMRA MarketRank™: Damora Therapeutics, Inc. Common Stock scored higher than 55% of companies evaluated by MarketBeat, and ranked 398th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDamora Therapeutics, Inc. Common Stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDamora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, representing about 64.8% upside from its current price of $26.70.Amount of Analyst CoverageDamora Therapeutics, Inc. Common Stock has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Damora Therapeutics, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($2.06) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.71% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverDamora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 13.57, which indicates bearish sentiment.Change versus previous monthShort interest in Damora Therapeutics, Inc. Common Stock has recently decreased by 3.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDamora Therapeutics, Inc. Common Stock does not currently pay a dividend.Dividend GrowthDamora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.87 News SentimentDamora Therapeutics, Inc. Common Stock has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 3 articles on an average week.Search Interest1 people have searched for DMRA on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Damora Therapeutics, Inc. Common Stock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,345.00 in company stock.Percentage Held by Insiders0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.Percentage Held by Institutions14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.Read more about Damora Therapeutics, Inc. Common Stock's insider trading history. Receive DMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Damora Therapeutics, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMRA Stock News HeadlinesDamora Therapeutics Grants Inducement Awards To Three New EmployeesSeptember 3, 2026 | rttnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comTrump and Bernie agree on thisDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.September 10 at 1:00 AM | Porter & Company (Ad)Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives $44.00 Consensus PT from AnalystsAugust 31, 2026 | americanbankingnews.comDamora Therapeutics: Competition Validates The Target While Its Portfolio Creates The UpsideAugust 12, 2026 | seekingalpha.comDamora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsAugust 11, 2026 | tmcnet.comDamora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and MyelofibrosisAugust 6, 2026 | markets.businessinsider.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 3, 2026 | globenewswire.comSee More Headlines DMRA Stock Analysis - Frequently Asked Questions How have DMRA shares performed this year? Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 at the beginning of 2026. Since then, DMRA shares have increased by 16.0% and is now trading at $26.70. How were Damora Therapeutics, Inc. Common Stock's earnings last quarter? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.06. When did Damora Therapeutics, Inc. Common Stock's stock split? Damora Therapeutics, Inc. Common Stock's stock reverse split on Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Damora Therapeutics, Inc. Common Stock's major shareholders? Top institutional shareholders of Damora Therapeutics, Inc. Common Stock include Braidwell LP (2.62%), California State Teachers Retirement System (1.71%), Seven Fleet Capital Management LP (0.46%) and Squarepoint Ops LLC (0.02%). Insiders that own company stock include Hans T Schambye, Garrett Winslow and Lori Firmani. View institutional ownership trends. How do I buy shares of Damora Therapeutics, Inc. Common Stock? Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI). Company Calendar Last Earnings8/10/2026Today9/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DMRA's financial health is in the Green zone, according to TradeSmith. DMRA has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DMRA Previous SymbolNASDAQ:GLTO CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Damora Therapeutics, Inc. Common Stock$44.00 High Price Target$50.00 Low Price Target$40.00 Potential Upside/Downside+63.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-176.39% Return on Assets-77.86% Debt Debt-to-Equity RatioN/A Current Ratio19.73 Quick Ratio19.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($110.11) per share Price / Book-0.24Miscellaneous Outstanding Shares61,740,000Free Float61,489,000Market Cap$1.66 billion OptionableNo Data Beta1.46 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:DMRA) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Damora Therapeutics, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Damora Therapeutics, Inc. Common Stock With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMRA Stock Alerts